About: Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : wasabi.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19
Creator	Xu, Yang Li, Yong-Zhe Huang, Gang Dong, Sheng-Yong Xu, Y Zeng, Qiang Huang, G Xu, G Chen, Zong-Tao Jiangsu, ) Sciences, Health Xu, Guoqiang Zhong, Tian-Yu
Source	MedRxiv
abstract	The dynamic immunological characteristics of COVID-19 patients are essential for clinicians to understand the disease progression. Our data showed that the immune system and function have gradually remodeled and declined with age from 16-91 years old in 25,239 healthy controls. Analyzing the relationship between the number of lymphocytes and age showed that lymphocytes and subsets tended to decline with age significantly, whereas, the number of natural killer cells tended to increase with age significantly. SARS-CoV-2 specific immunity has declined with age in fatal cases. Furthermore, SARS-CoV-2 specific immunity is associated with survival time in fatal cases. The loss expansion of SARS-CoV-2 specific immunity could be expanded in vitro. A concurrent decline in SARS-CoV-2 specific cellular and humoral immunity and prolonged SARS-CoV-2 exposure predicted fatal outcomes. Our findings have provided a basis for further analysis of SARS-CoV-2 specific immunity and understanding the pathogenesis of fatal COVID-19 patients.
has issue date	2020-08-01(xsd:dateTime)
bibo:doi	10.1101/2020.07.29.20164681
has license	medrxiv
sha1sum (hex)	bb48837b4608479cafedb8c054f6aa8911541b19
schema:url	https://doi.org/10.1101/2020.07.29.20164681
resource representing a document's title	Loss expansion of SARS-CoV-2 specific immunity is a key risk factor in fatal patients with COVID-19
resource representing a document's body	covid:bb48837b4608479cafedb8c054f6aa8911541b19#body_text
is schema:about of	named entity 'SARS-CoV-2' named entity 'CELLULAR' named entity 'PREPRINT' named entity 'PREDICTED' named entity 'EXPANDED ' named entity 'ABSTRACT' named entity 'concurrent' named entity 'immunity' named entity 'fatal' named entity 'gradually' named entity 'SARS-CoV-2' named entity 'survival time' named entity 'SARS-CoV-2' named entity 'cellular immunity' named entity 'survival time' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'SARS-CoV-2' named entity 'high-risk groups' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'SARS-CoV-2' named entity 'specific immunity' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'humoral immunity' named entity 'peer review' named entity 'viral load' named entity 'preprint' named entity 'SARS-CoV-2' named entity 'IgG' named entity 'SARS-CoV-2' named entity 'survival time' named entity 'preprint' named entity 'COVID' named entity 'COVID-19 disease' named entity 'COVID' named entity 'titer' named entity 'peer review' named entity 'COVID' named entity 'specific immunity' named entity 'SARS-CoV-2' named entity 'titer' named entity 'SARS-CoV-2' named entity 'preprint' named entity 'IFNγ' named entity 'preprint' named entity 'humoral immunity' named entity 'preprint' named entity 'CD8 T cells' named entity 'IgG antibodies' named entity 'SARS-CoV-2' named entity 'specific immunity' named entity 'preprint' named entity 'viral load' named entity 'medRxiv' named entity 'flow cytometry' named entity 'Coronavirus disease 2019' named entity 'SARS-CoV-2' named entity 'COVID' named entity 'preprint' named entity 'preprint' named entity 'specific immunity' named entity 'SARS-CoV-2' named entity 'severe acute respiratory syndrome coronavirus 2' named entity 'survival time' named entity 'SARS-CoV-2' named entity 'elderly people' named entity 'peer review' named entity 'lymphocyte subsets' named entity 'medRxiv' named entity 'SARS-CoV-2'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software